Eli Lilly and Company News - June 2026
🔴 LLY is trading 2.3% down today as investors reassess GLP-1 economics after Medicare's Wegovy pilot
LLY is trading 2.3% down at $1201.96 as investors reassess GLP-1 economics following Medicare’s new Wegovy obesity-drug pilot and broader weight-loss coverage...
🟢 LLY up 4.1% today as Eli Lilly's Jaypirca receives positive EU recommendation for CLL
Eli Lilly (LLY) is trading 4.1% up at $1,173.96 today, following a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products...
Eli Lilly offers Zepbound for $50, targeting 20 million Medicare patients
Eli Lilly and Company will launch its Medicare GLP-1 Bridge program on July 1, 2026. Eligible Medicare Part D patients will pay $50 per month for Zepbound...
🟢 LLY is trading 2.2% up today after a $1.9B Abbisko deal and China obesity drug optimism
LLY is trading 2.2% up at $1141.61 following news of a potential $1.9 billion research collaboration with Abbisko Therapeutics. • The partnership is...
Lilly Inks $1.9B R&D Deal, Eyes Late 2026 China Launch for Oral Obesity Drug
Eli Lilly announced a research and development collaboration with Chinese drug developer Abbisko Therapeutics potentially worth up to $1.9 billion. [6, 8]...
Eli Lilly Surges 4.6% on Weight-Loss Drug Euphoria and Big-Money Buying — But Can the Stock Keep Outrunning Its Own Hype?
Shares of Eli Lilly jumped 4.6% to $1,127.99 on June 4, snapping a week-long slide that saw the stock drop from $1,126.80 to $1,064.15 in just five sessions....
🟢 Eli Lilly is trading 4.6% up today on a new $1.9B genetic medicine deal and a Weight Watchers partnership
Eli Lilly and Company is trading 4.6% up at $1127.99 following the announcement of a major research partnership and expanded access for its weight-loss drug...
Eli Lilly inks $4.2B in Asian drug deals to bolster pipeline
Eli Lilly and Company signed two significant licensing agreements in Asia on June 1, 2026. The company partnered with China’s Haisco Pharmaceutical in a...